Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...

The third time is not the charm for Hengrui Pharma and Elevar Therapeutics’ star-crossed combination of camrelizumab and ...

This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the ...

In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals ...

The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...

Amid restructuring efforts, Bayer has addressed its need for a capital infusion in pharma under a deal to secure 3 billion ...

After several months of AbbVie leading pharma’s monthly ad spend, Johnson & Johnson is back as Tremfya topped June’s rankings ...

Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...

The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...

Aiming to streamline the compensation process for people claiming harm from COVID-19 vaccines, Robert F. | Aiming to ...

The comment-seeking period and probe tie back to Sanofi’s marketing for its flu shot for adults ages 60 and over, which is ...

When launching a drug as big as semaglutide, even as a generic, the market expectations are immense, and any fumble on the ...